@article{Kravchun_2016, title={EVIDENCE BASE OF SITAGLIPTIN CLINICAL USE. 10 YEARS IN THE MARKET OF THE WORLD}, volume={56}, url={https://jpep.endocrinology.org.ua/index.php/1/article/view/387}, DOI={10.21856/j-PEP.2016.2.11}, abstractNote={<p>A review of the scientific literature about treatment of patients with type 2 diabetes mellitus with the help of the first approved drug from the group of DPP-4 inhibitor sitagliptin was presented. The effects of the treatment of sitagliptin on carbohydrate metabolism, bone metabolism, evaluation of cardiovascular safety were given.</p>}, number={2}, journal={Problems of Endocrine Pathology}, author={Kravchun, N.}, year={2016}, month={Jun.}, pages={74-79} }